Selecting the Appropriate Patients With MM for Treatment With Isa-Kd

Video

Oncologists debate which patient populations most benefit from isatuximab plus carfilzomib and dexamethasone.

Related Videos
S. Vincent Rajkumar, MD
Muhamed Baljevic, MD
Sundar Jagannath, MBBS
Sundar Jagannath, MBBS
Video  10 -"Real-World Evidence on Second-Line Therapy Selection and Outcomes"
Video  9 - "Additional Second-Line Treatments for HCC"
James Ignatz-Hoover, MD, PhD
Sundar Jagannath, MBBS
Elias Jabbour, MD
A panel of 4 experts on colorectal cancer